Robotic versus laparoscopic distal gastrectomy in patients with gastric cancer: a propensity score-matched analysis

Taro Isobe*, Naotaka Murakami, Taizan Minami, Yuya Tanaka, Hideaki Kaku, Yuki Umetani, Junya Kizaki, Keishiro Aoyagi, Fumihiko Fujita and Yoshito Akagi

Abstract

Background: Robotic distal gastrectomy (RDG) has been increasingly used for the treatment of gastric cancer (GC). However, whether RDG has a clinical advantage over laparoscopic distal gastrectomy (LDG) is yet to be determined. Thus, this study aimed to assess the feasibility and safety of RDG for the treatment of GC as compared with LDG.

Methods: In total, 157 patients were enrolled between February 2018 and August 2020 in this retrospective study. We then compared the surgical outcomes between RDG and LDG using propensity score-matching (PSM) analysis to reduce the confounding differences.

Results: After PSM, a clinicopathologically well-balanced cohort of 100 patients (50 in each group) was analyzed. The operation time for the RDG group (350.1 ± 58.1 min) was determined to be significantly longer than that for the LDG group (257.5 ± 63.7 min; \( P < 0.0001 \)). Of interest, there was a decreased incidence of pancreatic fistulas and severe complications after RDG as compared with LDG (\( P = 0.092 \) and \( P = 0.061 \), respectively). In addition, postoperative hospital stay was statistically slightly shorter in the RDG group as compared with the LDG group (12.0 ± 5.6 vs. 13.0 ± 12.3 days; \( P = 0.038 \)).

Conclusions: Our study confirmed that RDG is a feasible and safe procedure for GC in terms of short-term surgical outcomes. A surgical robot might reduce postoperative severe complications and length of hospital stay.

Keywords: Robotic gastrectomy, Laparoscopic gastrectomy, GC, Short-term outcomes

Background

Gastric cancer (GC) has been identified as one of the most common causes of cancer-related mortality worldwide [1]. Radical gastrectomy with regional lymphadenectomy is still considered as the only curative treatment for GC [2, 3]. Since Kitano et al. first performed laparoscopically assisted gastrectomy for GC in 1991, minimally invasive surgery with laparoscopy has gradually been accepted as a common surgical procedure for GC patients [4]. Several reports have shown the advantages of laparoscopic distal gastrectomy (LDG) as compared with open gastrectomy, which include less invasiveness and pain, better cosmetic outcomes, rapid return of gastrointestinal function, and shorter hospital stay [5–7]. However, the current laparoscopic procedure has been determined to have some technical limitations, including two-dimensional visualization, straight rigid instruments, amplified physiologic tremor, and the uncomfortable position required for surgeons. The da Vinci surgical system (Intuitive Surgical, Inc., Sunnyvale, CA), which provides surgeons with high-resolution three-dimensional images, wristed instruments offering...
seven degrees of freedom, and tremor filtration technology, has been identified to be capable of overcoming the lack of perspectives and maneuverability restrictions in laparoscopic surgery. In 2003, Hashizume and Sugimachi were the first to use robotic gastrectomy (RG) for the treatment of GC [8]. In April 2018, RG was approved for national medical insurance coverage in Japan; since then, the number of RG procedures performed in this country has seen a significant increase [9]. Several studies have compared the safety and feasibility of robotic distal gastrectomy (RDG) and LDG [2, 10, 11]. However, most of these studies did not take all the background data into consideration. Therefore, in terms of safety and feasibility, whether RG should be recommended as the standard surgical treatment for GC is still controversial. Thus, this study aimed to assess the short-term surgical outcomes between RDG and LDG using propensity score-matching (PSM) analysis to adjust for patient background data as far as possible.

Methods

Patients

This present study was performed in accordance with the principles of the Declaration of Helsinki. This study was approved by the ethical committee of Kurume University (approval No. 19201). All patients provided a written informed consent for their operations. We retrospectively collected data from a prospective database of Kurume University Hospital. We used the following as inclusion criteria for the study: all patients diagnosed with GC via pathological biopsy and those with clinical T1-4N0-3M0 GC based on the Japanese classification of gastric carcinoma (JCGC) [12]. We then excluded the following patients: those with indications for endoscopic submucosal dissection, those with large (≥8 cm) macroscopic type 3 cancer or type 4 cancer and bulky lymph node (LN) metastasis, those requiring splenectomy, those with distant metastasis and remnant stomach cancer, and those who had prior chemotherapy or radiotherapy for any malignancy or prior upper abdominal surgery or intestinal resection other than appendectomy or cholecystectomy. Tumors were classified according to the JCGC, and terminology was also used in accordance with the JCGC.

Between February 2018 and August 2020, we were able to perform RDG in total 69 patients and LDG in 88 patients with GC at Kurume University Hospital. Clinico-pathological characteristics [such as age, gender, body mass index (BMI), tumor status, American Society of Anesthesiologists performance status (ASA-PS) classification, and comorbidity] and short-term outcomes [including operative time, blood loss, conversion to another method, extent of resection, reconstruction, extent of LN dissection, postoperative morbidity and mortality, postoperative hospital stay, maximum plasma C-reactive protein (CRP) levels, and drain amylase (D.AMY) concentration in the drainage fluid at postoperative day 3] were also determined and compared between the two groups. Postoperative complications were considered for those with Clavien–Dindo classification (CDC) grade II or greater that occurred within 30 days after gastrectomy [13]. If a patient had multiple complications, we utilized the complication with the highest grade for the analysis.

Surgical procedures

All gastrectomy procedures were performed according to the standard of radical gastrectomy based on the Japanese GC treatment guidelines [14]. The procedures employed during RDG are not different from those of LDG except for the use of articulating robotic instruments. During surgery, patients were placed in a supine and reverse Trendelenburg position, with legs elevated approximately 15°–20°. Both surgical procedures used a total of five trocars. RDG was performed using the da Vinci surgical system Xi with four articulating arms: one central arm for a 30° rigid dual-channel endoscope and the remaining three for a Cadiere forceps, fenestrated bipolar forceps, and bipolar Maryland forceps or Vessel Sealer system. One assistant port was placed at the right umbilical level. When Billroth-I reconstruction was technically possible, we used a Delta-shaped anastomosis. When Billroth-I reconstruction could not be used, we applied instead Billroth-II or Roux-en-Y reconstruction based on the preference of the operating surgeon. A single abdominal drainage tube was inserted into the left subphrenic cavity after reconstruction.

PSM analysis

We performed PSM analysis to remove the confounding factors and overcome possible patient selection bias. For all patients, the propensity score was calculated using a logistic regression model based on the following variables: age, gender, BMI, ASA-PS, history of abdominal operation, comorbidity, tumor size, histology, pT stage, pN stage, and pTNM stage. A 1:1 nearest-neighbor matching algorithm with an optimal caliper width of 0.20 without replacement was used in matching the propensity score. After PSM, the balance of variables between the two groups was assessed by calculating the standardized mean difference (SMD). An SMD < 0.10 of the absolute value was considered to be a sufficient balance.

Statistical analysis

All statistical analyses were performed using the JMP software, version 14 (SAS Institute Inc., Cary, NC,
USA). Categorical variables were compared using the Pearson's \( \chi^2 \) test or Fisher's exact test, whereas normally distributed continuous variables were expressed as mean ± standard deviation and analyzed using Student's \( t \)-test. Nonparametric continuous values were expressed as median (interquartile range) and were compared using the Mann–Whitney \( U \) test. A \( p \)-value < 0.05 was considered to be statistically significant.

### Results

#### Clinicopathological characteristics

From February 2018 to August 2020, total 157 GC patients (69 RDG, 88 LDG) at Kurume University Hospital were identified. Table 1 summarizes the clinicopathological characteristics of all patients and matched patients. Before PSM, the mean age of the RDG group was determined to be significantly younger than that of the LDG group (66.9 ± 10.2 and 72.3 ± 10.1 years, respectively; \( P < 0.001 \)), and the mean BMI of the RDG group was significantly lower than that of the LDG group.

| Table 1 Clinicopathological findings before and after matching |
|------------------|------------------|-------------------|------------------|-------------------|
|                   | Entire cohort    | Propensity-score matched cohort |                   |
|                   | RDG (n = 69)     | LDG (n = 88)       | RDG (n = 50)     | LDG (n = 50)       |
| Age (years)       | 66.9 ± 10.2      | 72.3 ± 10.1        | 69.2 ± 1.4       | 69.3 ± 1.4         | 0.942 |
| Gender            |                  |                   |                  |                   |
| Male              | 45 (65.2%)       | 58 (65.9%)         | 31 (62.0%)       | 34 (68.0%)         | 0.529 |
| Female            | 24 (34.8%)       | 30 (34.1%)         | 19 (38.0%)       | 16 (32.0%)         |       |
| BMI (kg/m²)       | 22.4 ± 3.5       | 23.5 ± 3.1         | 23.0 ± 3.6       | 22.9 ± 2.7         | 0.893 |
| Previous abdominal operation |                |                   |                  |                   |
| No                | 47 (68.1%)       | 57 (64.8%)         | 32 (64.0%)       | 33 (66.0%)         | 0.834 |
| Yes               | 22 (31.9%)       | 31 (35.2%)         | 18 (36.0%)       | 17 (34.0%)         |       |
| Comorbidity       |                  |                   |                  |                   |
| No                | 22 (31.9%)       | 17 (19.3%)         | 13 (26.0%)       | 14 (28.0%)         | 0.822 |
| Yes               | 47 (68.1%)       | 71 (80.7%)         | 37 (74.0%)       | 36 (72.0%)         |       |
| ASA PS score      |                  |                   |                  |                   |
| I                 | 18 (26.1%)       | 16 (18.2%)         | 12 (24.0%)       | 13 (26.0%)         | 0.886 |
| II                | 48 (69.6%)       | 52 (59.1%)         | 35 (70.0%)       | 33 (66.0%)         |       |
| III               | 3 (4.3%)         | 20 (22.7%)         | 3 (6.0%)         | 4 (8.0%)           |       |
| Tumor size (mm)   | 30.0 ± 14.6      | 35.0 ± 23.3        | 31.8 ± 15.1      | 30.4 ± 17.6        | 0.666 |
| Histological type |                  |                   |                  |                   |
| Differentiated    | 38 (55.1%)       | 47 (53.4%)         | 28 (56.0%)       | 26 (52.0%)         | 0.688 |
| Undifferentiated  | 31 (44.9%)       | 41 (46.6%)         | 22 (44.0%)       | 24 (48.0%)         |       |
| pT classification |                  |                   |                  |                   |
| T1                | 48 (69.6%)       | 55 (62.5%)         | 33 (66.0%)       | 33 (66.0%)         | 0.853 |
| T2                | 8 (11.6%)        | 7 (8.0%)           | 5 (10.0%)        | 3 (6.0%)           |       |
| T3                | 6 (8.7%)         | 10 (11.4%)         | 6 (12.0%)        | 8 (16.0%)          |       |
| T4                | 7 (10.1%)        | 16 (18.2%)         | 6 (12.0%)        | 6 (12.0%)          |       |
| pN classification |                  |                   |                  |                   |
| N0                | 56 (81.2%)       | 59 (67.1%)         | 38 (76.0%)       | 39 (78.0%)         | 0.976 |
| N1                | 3 (4.4%)         | 11 (12.5%)         | 3 (6.0%)         | 3 (6.0%)           |       |
| N2                | 7 (10.1%)        | 7 (8.0%)           | 6 (12.0%)        | 6 (12.0%)          |       |
| N3                | 3 (4.4%)         | 11 (12.5%)         | 3 (6.0%)         | 2 (4.0%)           |       |
| pStage            |                  |                   |                  |                   |
| I                 | 51 (73.9%)       | 56 (63.6%)         | 34 (68.0%)       | 34 (68.0%)         | 0.937 |
| II                | 11 (15.9%)       | 15 (17.1%)         | 9 (18.0%)        | 10 (20.0%)         |       |
| III               | 7 (10.1%)        | 17 (19.3%)         | 7 (14.0%)        | 6 (12.0%)          |       |

**BMI**: body mass index, **ASA**: American Society of Anesthesiologists, **PS**: performance status

\*\( P < 0.05 \) indicates statistical significance
(22.4 ± 3.5 and 23.5 ± 3.1 kg/m², respectively; \( P = 0.044 \)). In addition, the ASA-PS score of the RDG group was significantly lower than that of the LDG group (\( P = 0.005 \)). There were no significant differences between groups in terms of gender, previous abdominal operation, comorbidity, or tumor status. Based on the PSM, we selected 50 patients who underwent RDG and 50 patients who underwent LDG. After adjusting for background factors by PSM, the patient distributions were well balanced between the RDG and LDG groups. In both groups, stage I cancer rate was 68%.

**Surgical outcome**

Table 2 summarizes the details of the surgical outcomes in the matched groups. No significant between-group differences were determined in the degree of LN dissection or method of reconstruction. None of the operations were converted to an open procedure in either group, or there was no laparoscopic conversion in the RDG group. The operation time for the RDG group (350.1 ± 58.1 min) was significantly longer than that for the LDG group (257.5 ± 63.7 min; \( P < 0.0001 \)). The difference between both groups in the mean number of retrieved LNs, blood loss, maximum plasma CRP levels, and D.AMY concentration in drainage fluid on postoperative day 3 was not significant. The median postoperative hospital stay was slightly shorter in the RDG group than that in the LDG group (12.0 ± 5.6 vs. 13.0 ± 12.3 days; \( P = 0.038 \)).

No treatment-related deaths and rehospitalizations were recorded.

**Postoperative complications**

Table 3 details the incidence of postoperative complications. In total, 7 patients (14.0%) incurred complications after RDG, compared with 10 patients (20.0%) who experienced complications after LDG (\( P = 0.425 \)). The incidence of postoperative complications was nearly similar in both RDG and LDG groups. There tended be fewer pancreatic fistula and severe complications (CDC grade III or higher) in the RDG group as compared with the LDG group (2.0 and 10.0%; \( P = 0.092 \); 2.0 and 14.0%; \( P = 0.061 \), respectively). Only one (2.1%) patient in the RDG group had a CDC grade IIIa surgical complication (anastomotic leakage). No patient in either group required reoperation or surgical intervention.

**Total cost**

In the RDG group, the total medical cost, including the operative fee and admission expense, was 1,808,998 (1,595,166–2,465,620) JPY, and in the LDG group, it was 1,836,041 (1,509,508–4,103,092) JPY (\( P = 0.195 \)).

**Discussion**

In recent years, minimally invasive surgery has been rapidly developed and improved, thereby providing a new alternative surgical method for the treatment of early-stage GC, for which it has gradually become the mainstream surgical treatment [2, 3]. However, there

---

**Table 2** Details of surgical outcomes in the matched groups

| Lymph node dissection | RDG (n = 50) | LDG (n = 50) | \( P \) value |
|-----------------------|-------------|-------------|--------------|
| D1                    | 2 (4.0%)    | 3 (6.0%)    | 0.790        |
| D1+                   | 26 (52.0%)  | 23 (46.0%)  |              |
| D2                    | 22 (44.0%)  | 24 (48.0%)  |              |
| Number of retrieved LNs | 45.7 ± 18.1 | 44.9 ± 16.8 | 0.819        |
| Reconstruction method |             |             |              |
| BI                    | 35 (70.0%)  | 25 (50.0%)  | 0.107        |
| BII                   | 3 (6.0%)    | 7 (14.0%)   |              |
| RY                    | 12 (24.0%)  | 18 (36.0%)  |              |
| Open conversion       | None        | None        |              |
| Operation time (min)  | 350.1 ± 58.1| 270.5 ± 63.7| <0.0001*     |
| Blood loss (ml)       | 12.5 ± 70.1 | 15.0 ± 36.3 | 0.234        |
| CRP (mg/dl)           | 12.0 ± 5.5  | 11.7 ± 6.5  | 0.606        |
| D.AMY (U/L)           | 96.0 ± 318.6| 144.0 ± 498.2| 0.105        |
| Postoperative hospital stay (days) | 12.0 ± 5.6 | 13.0 ± 12.3 | 0.038*       |
| Mortality             | None        | None        |              |

\( BI \) Billroth I reconstruction, \( BII \) Billroth II reconstruction, \( RY \) Roux en Y reconstruction, LN lymph node, CRP C-reactive protein, D.AMY drain amylase

\( *P < 0.05 \) indicates statistical significance

**Table 3** Postoperative complications in the matched groups

| Postoperative complications | RDG (n = 50) | LDG (n = 50) | \( P \) value |
|-----------------------------|-------------|-------------|--------------|
| Anastomotic leakage         | 2 (4.0%)    | 1 (2.0%)    | 0.558        |
| Pancreas fistula            | 1 (2.0%)    | 5 (10.0%)   | 0.092        |
| Leakage of lymphatics       | 2 (4.0%)    | 0           | 0.153        |
| Intra-abdominal abscess     | 1 (2.0%)    | 2 (4.0%)    | 0.558        |
| Pneumonia                   | 0           | 1 (2.0%)    | 0.315        |
| Other                       | 4 (8.0%)    | 3 (6.0%)    | 0.695        |
| Cholecystitis               | 0           | 1           |              |
| Liver infarction            | 1           | 0           |              |
| Liver abscess               | 0           | 1           |              |
| Stomal ulcer                | 2           | 0           |              |
| Delayed gastric emptying    | 1           | 1           |              |
| Complication grade (CDC)    |             |             |              |
| Grade II                    | 6 (12.0%)   | 3 (6.0%)    | 0.061        |
| Grade III                   | 1 (2.0%)    | 7 (14.0%)   |              |
| Grade IV/V                  | 0           | 0           |              |

CDC Clavien–Dindo classification

\( *P < 0.05 \) indicates statistical significance
are still some technical limitations to laparoscopic surgery, so the minimally invasive approach for advanced GC that requires D2 LN dissection has not achieved a worldwide consensus yet [15, 16]. Robotic surgery has advantages over conventional laparoscopic surgery in terms of tremor filtering, clarity of the surgical view in three dimensions, and improved dexterity with the articulated arm [8, 15]. RG is an alternative minimally invasive surgical technique that has been gradually used for the treatment of GC [17, 18]. However, clinically significant benefits of RG have yet to be sufficiently proven.

Several studies have compared RDG and LDG, but the outcomes of some of these studies differed in terms of operative time, blood loss, number of resected LNs, and rate of complications [2, 10, 11, 19, 20]. This study showed that the operative time was significantly longer in the RDG group as compared with the LDG group, which may be attributed to the additional time required for docking and preparation and reduced surgeons’ less experience with the use of this novel robotic modality. Operation time was also longer when LDG was initially adopted. As surgeons have gained experience using this technique, the operation time for LDG has gradually decreased. Similar trends may be anticipated for RDG.

Some studies have found no difference in operation time between robotic and laparoscopic surgery when performed by an experienced surgeon. Huang et al. reported that both operating time and docking time decreased and stabilized after 25 procedures for RG and after 41 procedures for laparoscopic gastrectomy for experienced surgeons [21]. The learning curve for the da Vinci surgical system is extremely short for surgeons, with sufficient experience performing conventional laparoscopic gastrectomy.

Our study showed that the difference in the mean number of retrieved LNs and the mean amount of blood loss between groups was not significant. Several studies have reported the equivalence of RDG and LDG in terms of blood loss and LN dissection [11, 15–20]. The articulating instrument might have been responsible for the higher number of resected LNs, because it aids surgeons in reaching deep areas that would be otherwise unreachable when using laparoscopic straight forceps. In particular, articulating instruments could prevent injuries to the blood vessels, such as the common hepatic artery, celiac trunk, and splenic artery, and allow precise dissection, particularly in the inferior pylorus area and the suprapancreatic area, which are technically demanding in laparoscopic surgery. In this study, a prolonged operative time did not affect the short-term surgical outcomes. In other words, although RDG requires a longer operative time as compared with LDG, the need for less surgical manipulation during robotic surgery may lead to lower surgical stress among patients.

When assessing the quality and safety of operations, determining any presence of postoperative complication is also an important consideration [22, 23]. Obama et al. reported no differences in the incidence of overall or major complications between patients undergoing RDG and LDG [24]. On the other hand, in their multinational prospective study, Uyama et al. reported the advantages of RDG in terms of reduced postoperative complications [9]. In this study, we observed that the incidence of postoperative complications was almost similar between the RDG and LDG groups. However, there tended to be a lower rate of pancreatic fistula in the RDG group as compared with the LDG group. Pancreatic fistula, which is one of the most troublesome and potentially lethal complications after gastrectomy, results from injury to the pancreatic tissue during the surgical manipulation of the inferior pylorus area and the suprapancreatic area with excessive retraction of the pancreatic body. The reason for the lower rate of this complication in our study might be that the meticulous precision of the robotic articulated arm has likely reduced injury to the pancreas. However, major complications (CDC grade ≥ IIIa) observed in seven cases (14.0%) were determined to be more frequent in the LDG group than those observed in only one case (2.3%) in the RDG group. In their study, Hyun et al. reported that the RDG group had a higher total number of complications compared with the LDG group, but most of those complications were minor and could be treated nonsurgically [25]. As a result of fewer severe complications, the duration of the postoperative hospital stay was shorter in the RDG group as compared with the LDG group.

The perceived additional cost associated with robotic surgeries is a common issue. The total difference in cost between the LDG and RDG groups has been predicted to be around 3,900 USD, which is mainly derived from the robotic system itself [26]. Although robotic surgery device is currently monopolized by one company, hopefully in the near future, the cost will reduce when similar devices are developed and sold by other companies. In this study, the total medical cost was almost similar between the RDG and LDG groups. Another prospective study by Uyama et al. has shown that complications are associated with increased cost [9]. Reduced length of ICU admission or overall stay has an effect on the cost [27]. Not only do postoperative complications lead to a longer hospital stay and higher medical expenses but also, they have been reported to worsen the survival rate after curative gastrectomy [21, 28]. Most previous reports have failed to demonstrate clear clinical advantages of RDG over LDG [11, 18–20]. However, in this study, we
identified the benefits of RDG for reducing morbidity. A reduced morbidity by robotic surgery may decrease the total medical cost and duration of hospital stay and improve the quality of life and survival rate of patients. This study had several limitations. First, it was a single-institute, retrospective study. Although a randomized controlled trial was not performed, we used PSM analysis to reduce selection bias as far as possible, but the patient backgrounds cannot be fully corrected. Second, the study’s sample size was not large enough, and more than half of the patients had stage I cancer. Finally, we did not investigate long-term oncological outcomes, including late complications, recurrence, or survival.

Conclusions
This study demonstrated that RDG is a technically feasible and safe procedure for the treatment of patients with early-stage GC in terms of short-term surgical outcomes. We believe that, in the near future, RDG may be a practical and feasible alternative to LDG for the treatment of GC. However, whether RDG is truly superior to LDG requires verification via large-scale randomized controlled trials.

Abbreviations
ASA-PS: American Society of Anesthesiologists performance status; BMI: Body mass index; CDC: Clavien–Dindo classification; CRP: C-reactive protein; D.AMY: Drain amylase; GC: Gastric cancer; JGSC: Japanese classification of gastric carcinoma; LDG: Laparoscopic distal gastrectomy; LNs: Lymph nodes; RDG: Robotic distal gastrectomy; PSM: Propensity score-matching.

Acknowledgements
The authors would like to thank Enago (www.enago.jp) for the English language review.

Authors’ contributions
TI, NM, and KA contributed to the study conceptualization and design, analysis, and interpretation. TM, YT, HK, and YU contributed to the acquisition and analysis of data. JK, FF, and YA contributed to writing and revision. All authors read and approved the final manuscript.

Funding
The study did not receive funding from any organization.

Availability of data and materials
All data are included in the manuscript. The datasets used and analyzed during the current study available from the corresponding author upon reasonable request.

Declarations
Ethics approval and consent to participate
The institutional review board of Kurume University approved this retrospective study and waived the requirement for individual patient consent (approval no. 19201).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no conflict of interest.

References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
2. Suda K, Man IM, Ishida Y, Kawamura Y, Satoh S, Uyama I. Potential advantages of robotic radical gastrectomy for gastric adenocarcinoma in comparison with conventional laparoscopic approach: a single institutional retrospective comparative cohort study. Surg Endosc. 2015;29:673–85.
3. Uyama I, Suda K, Satoh S. Laparoscopic surgery for advanced gastric cancer: current status and future perspectives. J Gastric Cancer. 2013;13:19–25.
4. Kitano S, Iyo M, Moriyama M, Sugimachi K. Laparoscopy-assisted Billroth I gastrectomy. Surg Laparosc Endosc. 1994;4:146–8.
5. Katai H, Saito M, Fukuda H, Nakamura K, Hiki N, Saka M, et al. Safety and feasibility of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage I gastric cancer: a multicenter phase II trial (JCOG0703). Gastric Cancer. 2010;13:238–44.
6. Songun I, Putter H, Kranenberg EM, Saito M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of randomized nationwide Dutch D1 D2 trial. Lancet Oncol. 2010;11:439–49.
7. Kodera Y, Fujiwara M, Ohashi N, Nakayama G, Koike M, Morita S, et al. Laparoscopic surgery for gastric cancer: a collective review with meta-analysis of randomized trials. J Am Coll Surg. 2010;211:677–86.
8. Hashizume M, Sugimachi K. Robot-assisted gastric surgery. Surg Clin N Am. 2003;83:1329–49.
9. Uyama I, Suda K, Nakauchi K, Kinoshita T, Noshiro H, Takiguchi S, et al. Clinical advantages of robotic gastrectomy for clinical stage II/III gastric cancer: a multi-institutional prospective single-arm study. Gastric Cancer. 2019;22:377–85.
10. Hikage M, Tokunaga M, Makuchi R, Irimo T, Tanizawa Y, Bando E, et al. Comparison of surgical outcomes Between robotic and laparoscopic distal gastrectomy for cT1 gastric cancer. World J Surg. 2018;42:1803–10.
11. Liu HB, Wang WJ, Li HT, Han XP, Su L, Wei DW, et al. Robotic versus conventional laparoscopic gastrectomy for gastric cancer: A retrospective cohort study. Int J Surg. 2018;55:15–23.
12. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12.
13. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.
14. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver.3). Gastric Cancer. 2011;14:113–23.
15. Terashima M, Tokunaga M, Tanizawa Y, Bando E, Kawamura T, Mikata Y, et al. Robotic surgery for gastric cancer. Gastric Cancer. 2015;18:449–57.
16. De Manzoni G, Baiocchi GL, Frannarini M, De Giuli M, D’Ugo D, Marchet A, et al. The SIC-GIRCG 2013 Consensus Conference on Gastric Cancer. Updates Surg. 2014;66:1–6.
17. Van Boxel GJ, Ruurda JP, van Hillegersberg R. Robotic-assisted gastrectomy for gastric cancer: European perspective. Gastric Cancer. 2019;22:909–19.
18. Gutt CN, Omiu T, Mehrabi A, Kashi F, Schiermer F, Bäuchler MW. Robot-assisted abdominal surgery. Br J Surg. 2004;91:1390–7.
19. Ye SP, Shi J, Liu DN, Jiang QG, Lei X, Qiu H, et al. Robotic-assisted versus conventional laparoscopic-assisted total gastrectomy with D2 lymphadenectomy for advanced gastric cancer: short-term outcomes at a mono-institution. BMC Surg. 2019;19:186.
20. Wang WJ, Li R, Guo CA, Li HT, Li HT, Yu JP, Wang J, et al. Systematic assessment of complications after robotic-assisted total versus distal gastrectomy for advanced gastric cancer: a retrospective propensity score-matched study using Clavien-Dindo classification. Int J Surg. 2019;71:140–8.
21. Huang KH, Lan Y, Fang WL, Chen JH, Lo SS, Li AF, et al. Comparison of the operative outcomes and learning curves between laparoscopic and robotic gastrectomy for gastric cancer. PLoS One. 2014;9:e111499.
22. Tokunaga M, Tanizawa Y, Bando E, Kawamura T, Terashima M. Poor survival rate in patients with postoperative intra-abdominal infectious complications following curative gastrectomy for gastric cancer. Ann Surg Oncol. 2013;20:1575–83.

23. Kubota T, Hiki N, Sano T, Nomura S, Nunobe S, Kumagai K, et al. Prognostic significance of complications after curative surgery for gastric cancer. Ann Surg Oncol. 2014;21:891–8.

24. Obama K, Kim YM, Kang DR, Son T, Kim Hl, Noh SH, et al. Long-term oncologic outcomes of robotic gastrectomy for gastric cancer compared with laparoscopic gastrectomy. Gastric Cancer. 2018;21:285–95.

25. Hyun MH, Lee CH, Kwon YJ, Cho SI, Jang YJ, Kim DH, et al. Robot versus laparoscopic gastrectomy for cancer by an experienced surgeon: comparisons of surgery, complications, and surgical stress. Ann Surg Oncol. 2013;20:1258–65.

26. Ke Chen, Yu Pan, Bin Zhang, Maher H, Wang XF, Cai XJ. Robotic versus laparoscopic gastrectomy for gastric cancer: a systemic review and updated meta-analysis. BMC Surgery. 2017;17:93.

27. Van der Sluis PC, van der Horst S, May AM, Schippers C, Brosens LAA, Joore HCA, et al. Robot-assisted minimally invasive thoracolaparoscopic esophagectomy versus open transthoracic esophagectomy for resectable esophageal cancer: a randomized controlled trial. Ann Surg. 2019;269:621–30.

28. Fujiya K, Tokunaga M, Mori K, Makuuchi R, Tanizawa Y, Bando E, et al. Long-term survival in patients with postoperative intra-abdominal infectious complications after curative gastrectomy for gastric cancer: a propensity score matching analysis. Ann Surg Oncol. 2018;42:1803–10.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.